# DAFTAR PUSTAKA

Aher, R.B., Wanare, G., Kawathekar, N., Kumar, R.R., Kaushik, N.K., Sahal, D., Chauhan, V.S., 2011. Dibenzylideneacetone analogues as novel Plasmodium falciparum inhibitors. *Bioorg Med Chem Lett*, **21**, 3034–3036.

Alex, J.M., Kumar, R., 2014. 4,5-Dihydro-1H-pyrazole: an indispensable scaffold. *J Enzyme Inhib Med Chem*, **29**, 427–442.

Alex, K., Tillack, A., Schwarz, N., Beller, M., 2008. Zinc-Catalyzed Synthesis of Pyrazolines and Pyrazoles via Hydrohydrazination. *Org. Lett.*, **10**, 2377–2379.

Alsayari, A., Asiri, Y.I., Muhsinah, A.B., Hassan, M.Z., 2021. Anticolon Cancer Properties of Pyrazole Derivatives Acting through Xanthine Oxidase Inhibition. *Journal of Oncology*, **2021**, e5691982.

Anney, R. J. L., Lotfi-Miri, M., Olsson, C. A., Reid, S. C., Hemphill, S. A., Patton, G. C., 2007. Variation in the gene coding for the M5 muscarinic receptor (CHRM5) influences cigarette dose but is not associated with dependence to drugs of addiction: evidence from a prospective population based cohort study of young adults. *BMC Genetics*, **8**, 46.

Anonim, 2011, Exact Molecular Mass versus Molecular Weight, https://www.orgchemboulder.com/Spectroscopy/MS/molmassmw.shtml, 9 Desember 2024.

Ariefin, M., Alfanaar, R., 2023. Immobilization of Dibenzalacetone on TiO2 Surface and its Potential as Anti-UV Material. *Chempublish Journal*, **7**, 1–7.

Audousset, C., McGovern, T., Martin, J. G., 2021. Role of Nrf2 in Disease: Novel Molecular Mechanisms and Therapeutic Approaches - Pulmonary Disease/Asthma. *Frontiers in Physiology*, **12**, 727806.

Baek, G. H., Cheng, H., Choe, V., Bao, X., Shao, J., Luo, S., Rao, H., 2013. Cdc48: A Swiss Army Knife of Cell Biology. *Journal of Amino Acids*, **2013,** 183421.

Bagchi, S., Chhibber, T., Lahooti, B., Verma, A., Borse, V., & Jayant, R. D., 2019. In-vitro blood-brain barrier models for drug screening and permeation studies: An overview. *Drug Design, Development and Therapy*, **13**, 3591-3605.

Bandgar, B.P., Adsul, L.K., Chavan, H.V., Jalde, S.S., Shringare, S.N., Shaikh, R., Meshram, R.J., Gacche, R.N., Masand, V., 2012. Synthesis, biological evaluation, and docking studies of 3-(substituted)-aryl-5-(9-methyl-3-carbazole)-1H-2-pyrazolines as potent anti-inflammatory and antioxidant agents. *Bioorg Med Chem Lett*, **22**, 5839–5844.

Bansal, E., Srivastava, V.K., Kumar, A., 2001. Synthesis and anti-inflammatory activity of 1-acetyl-5-substitute daryl-3-(β-aminonaphthyl)-2-pyrazolines and β-(substitute daminoethyl) amidonaphthalenes. *European Journal of Medicinal Chemistry*, **36**, 81–92.

Bobola, M. S., Blank, A., Berger, M. S., Stevens, B. A., Silber, J. R., 2001. Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. *Clinical Cancer Research*, **7**(11), 3510-3518.

Budgett, R. F., Bakker, G., Sergeev, E., Bennett, K. A., Bradley, S. J., 2022. Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?. *Frontiers in Pharmacology*, **13**, 893422.

Byrne, R. & Schneider, G., 2019. In Silico Target Prediction for Small Molecules. *Methods Mol Biol*, **1888**, 273–309.

Carey, F. A. & Sundberg, R. J., 2000. *Advanced Organic Chemistry*, 4th Ed., Kluwer Academic, New York.

Chambers, N. E., Millet Jr., M., Moehle, M. S., 2023. The muscarinic M4 acetylcholine receptor exacerbates symptoms of movement disorders. *Biochemical Society Transactions*, **51**(2), 691-702.

ChemicalBook, 2024. Dibenzylideneacetone. https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3705221.htm, 8 Juli 2024.

Currie, G.M., 2018. Pharmacology, Part 2: Introduction to Pharmacokinetics. *J Nucl Med Technol*, **46**, 221–230.

Cuzzo, B., Padala, S.A., Lappin, S.L., 2024. Physiology, Vasopressin, in: StatPearls. StatPearls Publishing, Treasure Island (FL).

Dave, V. P. & Kaul, D., 2010. Coronary heart disease: Significance of liver X receptor α genomics. *World Journal of Cardiology*, **2**(6), 140-149.

Dawane, B.S., Konda, S.G., Mandawad, G.G., Shaikh, B.M., 2010. Poly(ethylene glycol) (PEG-400) as an alternative reaction solvent for the synthesis of some new 1-(4-(4'-chlorophenyl)-2-thiazolyl)-3-aryl-5-(2-butyl-4-chloro-1H-imidazol-5yl)-2-pyrazolines and their in vitro antimicrobial evaluation. *Eur J Med Chem*, **45**, 387–392.

de los Santos, J.M., López, Y., Aparicio, D., Palacios, F., 2008. A Convenient Synthesis of Substituted Pyrazolidines and Azaproline Derivatives through Highly Regio- and Diastereoselective Reduction of 2-Pyrazolines. *J. Org. Chem.*, **73**, 550–557.

de Oliveira, M.M., Nogueira, C.E.S., Almeida-Neto, F.W.Q., Santos, H.S., Teixeira, A.M.R., de Lima-Neto, P., Marinho, E.S., de Moraes, M.O., Pessoa, C., Barros-Nepomuceno, F.W.A., 2021. Full Spectroscopic Characterization and Cytotoxicity Activity of Synthetic Dibenzalacetone Derivatives. *Journal of Molecular Structure*, **1231**, 129670.

Di, L. & Kerns, E. H., 2016. *Drug-Like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization*, 2nd Ed., Academic Press, Cambridge.

Dong, X., 2018. Current Strategies for Brain Drug Delivery. *Theranostics*, **8**, 1481–1493.

Ecker, G., Chiba, P., Hitzler, M., Schmid, D., 1999. Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. *Biochemical Pharmacology*, **58**, 1447-1456.

Ekawati, L., Purwono, B., Mardjan, M.I.D., 2020. Synthesis N-Phenyl Pyrazoline from Dibenzalacetone and Heme Polymeration Inhibitory Activity (HPIA) Assay. *Key Engineering Materials*, **840**, 245–250.

Estabrook, R.W., 2003. A passion for P450s (rememberances of the early history of research on cytochrome P450). *Drug Metab Dispos*, **31**, 1461–1473.

Eteläinen, T.S., Silva, M.C., Uhari-Väänänen, J.K., De Lorenzo, F., Jäntti, M.H., Cui, H., Chavero-Pieres, M., Kilpeläinen, T., Mechtler, C., Svarcbahs, R., Seppälä, E., Savinainen, J.R., Puris, E., Fricker, G., Gynther, M., Julku, U.H., Huttunen, H.J., Haggarty, S.J., Myöhänen, T.T., 2023. A prolyl oligopeptidase inhibitor reduces tau pathology in cellular models and in mice with tauopathy. *Sci Transl Med*, **15**, eabq2915.

Fairley, L. H., Lai, K. O., Grimm, A., Eckert, A., Barron, A. M., 2024. The mitochondrial translocator protein (TSPO) in Alzheimer's disease: Therapeutic and immunomodulatory functions. *Biochimie*, **224**, 120-131.

Fenstermacher J, Gross P, Sposito N, Acuff V, Pettersen S, Gruber K., 1988. Structural and Functional Variations in Capillary Systems within the Braina. *Annals of the New York Academy of Sciences,* **529,** 21–30.

Fu, L., Shi, S., Yi, J., Wang, N., He, Y., Wu, Z., Peng, J., Deng, Y., Wang, W., Wu, C., Lyu, A., Zeng, X., Zhao, W., Hou, T., Cao, D., 2024. ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support. *Nucleic Acids Research*, **52**, W422–W431.

Garza, A.Z., Park, S.B., Kocz, R., 2023. Drug Elimination, in: StatPearls. StatPearls Publishing, Treasure Island (FL).

Gfeller, D., Grosdidier, A., Wirth, M., Daina, A., Michielin, O., Zoete, V., 2014. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. *Nucleic Acids Research*, **42**, W32.

Ghosh, M., Rana, S., 2023. The anaphylatoxin C5a: Structure, function, signaling, physiology, disease, and therapeutics. *International Immunopharmacology*, **118**, 110081.

Gomes, C. P., Fernandes, D. E., Casimiro, F., da Mata, G. F., Passos, M. T., Varela, P., Mastroianni-Kirsztajn, G., Pesquero, J. B., 2020. Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics. *Frontiers in Cellular and Infection Microbiology*, **10**, 589505.

Gottesman, M. M. & Pastan I., 1993. Biochemistry of multidrug resistance mediated by the multidrug transporter. *Annual Review of Biochemistry*, **62**, 385-427.

Groner, A.C., Cato, L., de Tribolet-Hardy, J., Bernasocchi, T., Janouskova, H., Melchers, D., Houtman, R., Cato, A.C.B., Tschopp, P., Gu, L., Corsinotti, A., Zhong, Q., Fankhauser, C., Fritz, C., Poyet, C., Wagner, U., Guo, T., Aebersold, R., Garraway, L.A., Wild, P.J., Theurillat, J.-P., Brown, M., 2016. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. *Cancer Cell*, **29**, 846–858.

Gu, Y., Yu, Z., Wang, Y., Chen, L., Lou, C., Yang, C., Li, W., Liu, G., Tang, Y., 2024. admetSAR3.0: a comprehensive platform for exploration, prediction and optimization of chemical ADMET properties. *Nucleic Acids Research*, **52**, W432.

Guo, H.-M., Wang, L.-T., Zhang, J., Zhao, P.-S., Jian, F.-F., 2008. Synthesis, IR Spectra, Crystal Structure and DFT Studies on 1-Acetyl-3-(4-

Chlorophenyl)-5-(4-Methylphenyl)-2-Pyrazoline. *Molecules*, **13**, 2039–2048. https://doi.org/10.3390/molecules13092039

Haider, K., Shafeeque, M., Yahya, S., Yar, M.S., 2022. A comprehensive review on pyrazoline based heterocyclic hybrids as potent anticancer agents. *European Journal of Medicinal Chemistry Reports*, **5**, 100042.

Halim, Y., 1994. Penentuan Parameter Lipofilitas Dari Ketoprofen Dan Fenbufen Dengan Cara Penentuan Nilai Log Poktanol Air Dan Perhitungan Tetapan Substituen Dari Hansch Dan Tetapan Frakmental Dari Rekker, *Skripsi*, Fakultas Farmasi Universitas Surabaya.

Hawkins, B.T. & Davis, T. P., 2005. The blood-brain barrier/neurovascular unit in health and disease. *Pharmacol Rev.*, **57**(2), 173-185.

He, Q., Zhang, G., Hou, D., Leng, A., Xu, M., Peng, J., Liu, T., 2011. Overexpression of sorcin results in multidrug resistance in gastric cancer cells with up-regulation of P-gp. *Oncology Reports*, **25**(1), 237-243.

Houshia, O., Walwil, A., Jumaa, H., Qrareya, H., Daraghmeh, H., Daraghmeh, I., Owies, A., Qushtom, A., 2019. Assessment of the Ratio of Geometric Isomers of Dibenzalacetone Spectroscopically. *Journal of Pharmaceutical Research International*, **31**(4), 1–9.

Kim, J. Y., Cho, H., Yoo, J., Kim, G. W., Jeon, Y. H., Lee, S. W., Kwon, S. H., 2022. Pathological Role of HDAC8: Cancer and Beyond. *Cells*, **11**(19), 3161.

Kniesel, U. & Wolburg, H., 2000. Tight junctions of the blood-brain barrier. *Cell Mol Neurobiol*., **20**(1), 57-76.

Kundavaram, R., Vinod, J., Mulukuri, S., 2017. Synthesis and Anti-Oxidant Activity of Dibenzalketones. *International Journal of Research in Pharmacy and Chemistry*, **7**, 585–606.

Lavecchia, A. & Cerchia, C., 2016. In silico methods to address polypharmacology: current status, applications and future perspectives. *Drug Discov Today*, **21**, 288–298.

Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced Drug Delivery Reviews, In Vitro Models for Selection of Development Candidates*, **23**, 3–25.

Liu, C., Zheng, D., Pu, X., Li, S., 2024. HDAC7: a promising target in cancer. *Frontiers in Oncology*, **14**, 1-10.

Liu, Y., Deguchi, Y., Tian, R., Wei, D., Wu, L., Chen, W., Xu, W., Xu, M., Liu, F., Gao, S., Jaoude, J. C., Chrieki, S. P., Moussalli, M. J., Gagea, M., Morris, J., Broaddus, R. R., Zuo, X., Shureiqi, I., 2019. Pleiotropic Effects of PPARD Accelerate Colorectal Tumorigenesis, Progression, and Invasion. *Cancer Research*, **79**(5), 954-969.

Mahé, O., Frath, D., Dez, I., Marsais, F., Levacher, V., Brière, J.-F., 2009. TBD-organocatalysed synthesis of pyrazolines. *Org. Biomol. Chem.*, **7**, 3648–3651.

Maibach, H. T., Brownstein, M. J., Hersch, S. M., Anderson, K. E., Itzkowitz, D. E., Damiano, E. M., Simon, N. G., 2022. The Vasopressin 1a Receptor

Antagonist SRX246 Reduces Aggressive Behavior in Huntington's Disease, *Journal of Personalized Medicine*, **12**(10), 1561.

Marbun, P., 2023. Prediction Of Pharmacokinetic Properties And In Silico Study Of 2,5 - Dibenzylidene Cyclopentanone Analogs As Oxidoreductase Inhibitor In Phase I Metabolism Targeting CYP3A4, *Skripsi*, Fakultas Farmasi Universitas Gadjah Mada.

Matiadis, D. & Sagnou, M., 2020. Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview. *IJMS*, **21**, 5507.

Matiadis, D., Sagnou, M., Karagiaouri, M., Pantazaki, A., Nowak, K.E., Mavroidi, B., Pelecanou, M., Katsipis, G., 2021. Synthesis and antimicrobial evaluation of a pyrazoline-pyridine silver(I) complex. *Biometals*, **34**, 67–85.

Mayersohn, M., 1987. Drug absorption. *J Clin Pharmacol*, **27**, 634–638.

McDonnell, A.M. & Dang, C.H., 2013. Basic Review of the Cytochrome P450 System. *J Adv Pract Oncol*, **4**, 263–268.

McMurry, J., 2004. *Organic Chemistry*, 6th Ed., Thomson Learning, Chicago.

Mishra, V.K., Mishra, M., Kashaw, V., Kashaw, S.K., 2017. Synthesis of 1,3,5-trisubstituted pyrazolines as potential antimalarial and antimicrobial agents. *Bioorg Med Chem*, **25**, 1949–1962.

Mijanović, O., Jakovleva, A., Branković, A., Zdravkova, K., Pualic, M., Belozerskaya, T. A., Nikitkina, A. I., Parodi, A., Zamyatnin Jr., A. A., 2022. Cathepsin K in Pathological Conditions and New Therapeutic and Diagnostic Perspectives. *International Journal of Molecular Sciences*, **23**(22), 13762.

Montero Vega, M. T. & de Andrés Martín, A., 2009. The significance of toll-like receptors in human diseases. *Allergologia et Immunopathologia*, **37**(5), 252-263.

Montoya, A., Quiroga, J., Abonia, R., Nogueras, M., Cobo, J., Insuasty, B., 2014. Synthesis and in Vitro Antitumor Activity of a Novel Series of 2-Pyrazoline Derivatives Bearing the 4-Aryloxy-7-chloroquinoline Fragment. *Molecules*, **19**, 18656.

Murga, C., Arcones, A. C., Cruces-Sande, M., Briones, A. M., Salaices, M., Mayor Jr., F., 2019. G Protein-Coupled Receptor Kinase 2 (GRK2) as a Potential Therapeutic Target in Cardiovascular and Metabolic Diseases. *Frontiers in Pharmacology*, **10**, 112.

Naim, M.J., Alam, O., Nawaz, F., Alam, Md.J., Alam, P., 2016. Current status of pyrazole and its biological activities. *J Pharm Bioallied Sci*, **8**, 2–17.

Nassar, A. F., Kamel, A. M., Clarimont, C., 2004. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. *Drug Discovery Today*, **9**(23), 1020-1028.

Nauduri, D. & Reddy, G.B., 1998. Antibacterials and antimycotics: Part 1: Synthesis and activity of 2-pyrazoline derivatives. *Chem Pharm Bull (Tokyo)*, **46**, 1254–1260.

Nelson, D.R., 2009. The cytochrome p450 homepage. *Hum Genomics*, **4**, 59–65.

Niccolini, F., Foltynie, T., Marques, T. R., Muhlert, N., Tziortzi, A. C., Searle, G. E., Natesan, S., Kapur, S., Rabiner, E. A., Gunn, R. N., Piccini, P., Politis,

M., 2015. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. *Brain*, **138**(10), 3003-3015.

Nickel, J., Gohlke, B.-O., Erehman, J., Banerjee, P., Rong, W.W., Goede, A., Dunkel, M., Preissner, R., 2014. SuperPred: update on drug classification and target prediction. *Nucleic Acids Research*, **42**, W26–W31.

Palioura, D., Lazou, A., Drosatos, K., 2023. Krüppel-like factor (KLF)5: An emerging foe of cardiovascular health. *Journal of Molecular and Cellular Cardiology*, **163**, 56-66.

Park, M. H. & Hong, J. T., 2016. Roles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches. *Cells*, **5**(2), 15.

Patel, V.M. & Desai, K.R., 2004. Eco-friendly synthesis of fluorine-containing pyrazoline derivatives over potassium carbonate. *Arkivoc*, **2004**, 123-129.

Pavia, D.L., Lampman, G.M., Kriz, G.S., Vyvyan, J.R., 2009. *Introduction to spectroscopy*, 4th Ed., Cengage Learning, Belmont.

Phang-Lyn, S. & Llerena, V.A., 2023. *Biochemistry, Biotransformation*, StatPearls Publishing, Treasure Island (FL).

Pope, C., 2022, Drug Half-life Explained, https://www.drugs.com/article/drug-half-life.html, 1 Desember 2024.

Purwaningsih, Y., Indriyanti, E., Syukur, M., Wigati, D., 2023. Synthesis of Dibenzalacetone using Sonochemistry and Its Antibacterial Activity Against Escherichia coli. *JKPK (Jurnal Kimia dan Pendidikan Kimia)*, **8**, 297–309.

Reddy, V. B., Shimada, S. G., Sikand, P., Lamotte, R. H., Lerner, E. A., 2010. Cathepsin S elicits itch and signals via protease-activated receptors. *The Journal of Investigative Dermatology*, **130**(5), 1468-1470.

Reul, J. M. H. M. & Holsboer, F., 2002. On the role of corticotropin-releasing hormone receptors in anxiety and depression. *Dialogues in Clinical Neuroscience*, **4**(1), 31-46.

Rice, J. E., 2014. *Organic Chemistry Concepts and Applications for Medicinal Chemistry*, Academic Press, Cambridge.

Rotondo, J. C., Mazziotta, C., Lanzillotti, C., Stefani, C., Badiale, G., Campione, G., Martini, F., Tognon, M., 2022. The Role of Purinergic P2X7 Receptor in Inflammation and Cancer: Novel Molecular Insights and Clinical Applications. *Cancers*, **14**(5), 1116.

Safaei, S., Mohammadpoor-Baltork, I., Khosropour, A.R., Moghadam, M., Tangestaninejad, S., Mirkhani, V., 2012. Diastereoselective Synthesis of Pyrazolines using a Bifunctional Brønsted Acidic Ionic Liquid under Solvent-Free Conditions. *Advanced Synthesis & Catalysis*, **354**, 3095–3104.

Sardjiman, S.S., Reksohadiprodjo, M.S., Hakim, L., van der Goot, H., Timmerman, H., 1997. 1,5-Diphenyl-1,4-pentadiene-3-ones and cyclic analogues as antioxidative agents. Synthesis and structure-activity relationship. *European Journal of Medicinal Chemistry*, **32**, 625–630.

Seelig, A., 1998. A general pattern for substrate recognition by P-glycoprotein. *European Journal of Biochemistry*, **251**(1), 252-261.

Senior, A. E., al-Shawi, M. K., Urbatsch, I. L., 1995. The catalytic cycle of P-glycoprotein. *FEBS Lett.*, **377**(3), 285-289.

Shahar Yar, M., Bakht, M.A., Siddiqui, A.A., Abdullah, M.M., De Clercq, E., 2009. Synthesis and evaluation of in vitro antiviral activity of novel phenoxy acetic acid derivatives. *J Enzyme Inhib Med Chem*, **24**, 876–882.

Sid, A., Messai, A., Parlak, C., Kazanci, N., Luneau, D., Keşan, G., Rhyman, L., Alswaidan, I., Ramasami, P., 2016. 1-Formyl-3-phenyl-5-(4-isopropylphenyl)-2-pyrazoline: Synthesis, characterization, antimicrobial activity and DFT studies. *Journal of Molecular Structure*, **1121**, 46–53.

SigmaAldrich, 2024. Trans,trans-Dibenzylideneacetone. https://www.sigmaaldrich.com/ID/en/product/aldrich/246425, 1 November 2024.

Singh, P., Negi, J.S., Nee Pant, G.J., Rawat, M.S.M., Budakoti, A., 2009. Synthesis and Characterization of a Novel 2-Pyrazoline. *Molbank*, **2009**, M614.

Slominski, A., 2009. On the role of the corticotropin-releasing hormone signalling system in the aetiology of inflammatory skin disorders. *The British journal of dermatology*, **160**, 229.

Smith, D. A., Beaumont, K., Maurer, T. S., & Di, L., 2015. Volume of Distribution in Drug Design. *Journal of Medicinal Chemistry*, **58**(15), 5691-5698.

Steinfeld, R., Reinhardt, K., Schreiber, K., Hillebrand, M., Kraetzner, R., Bruck, W., Saftig, P., Gartner, J., 2006. Cathepsin D deficiency is associated with a human neurodegenerative disorder. *American Journal of Human Genetics*, **78**(6), 988-998.

Sub Laban, T., Saadabadi, A., 2024. Monoamine Oxidase Inhibitors (MAOI), in: StatPearls. StatPearls Publishing, Treasure Island (FL).

Thomas, D. R., 5-ht5A receptors as a therapeutic target. *Pharmacology & Therapeutics*, **111**(3), 707-14.

Toutain, P.L., Bousquet-Mélou, A., 2004. Plasma clearance. *J Vet Pharmacol Ther*, **27**, 415–425.

Umemori, Y., Kuribayashi, K., Nirasawa, S., Kondoh, T., Tanaka, M., Kobayashi, D., Watanabe, N., 2014. Protein kinase C ζ regulates survivin expression and inhibits apoptosis in colon cancer. *International Journal of Oncology*, **45**(3), 1043-1050.

Vahedpour, T., Hamzeh-Mivehroud, M., Hemmati, S., Dastmalchi, S., 2021. Synthesis of 2-Pyrazolines from Hydrazines: Mechanisms Explained. *Chemistry Select*, **6**, 6483–6506.

Veber, D.F., Johnson, S.R., Cheng, H.-Y., Smith, B.R., Ward, K.W., Kopple, K.D., 2002. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. *J. Med. Chem.*, **45**, 2615–2623.

Wanat, K., 2020. Biological barriers, and the influence of protein binding on the passage of drugs across them. *Molecular Biology Reports*, **47**, 3221–3231.

Wahyuningsih, T.D., Suma, A., Astuti, E., 2019. Synthesis, anticancer activity, and docking study of N-acetyl pyrazolines from veratraldehyde. *Journal of Applied Pharmaceutical Science*, **9**, 14–20.

Wu, X.-F., Neumann, H., Beller, M., 2011. A Straightforward Synthesis of Pyrazolines and Pyrazoles: Palladium-Catalyzed Carbonylative Vinylation–Cyclocondensation Reactions of Aryl Halides. *European Journal of Organic Chemistry*, **2011**, 4919–4924.

Xu, X., Li, J., Zhang, Y., Zhang, L., 2021. Arachidonic Acid 15-Lipoxygenase: Effects of Its Expression, Metabolites, and Genetic and Epigenetic Variations on Airway Inflammation. *Allergy, Asthma & Immunology Research*, **13**, 684.

Xue, F., Jiang, T., Jiang, B., Cheng, X., He, Y., Li, X., Yang, X., 2014. Cardiac troponin I elevation with supraventricular tachycardia: two case reports and review of the literature. *BMC Research Notes*, **7**, 136.

Yanagita, H., Kanemasa, S., 2007. Synthesis of 3-(2-Pyridyl)-2-pyrazoline Derivatives (III) as Candidates for Heterocyclic Chiral Ligands of the Chirality Relay Types. *Cheminform*, **38**.

Zadorozhnii, P. V., Kiselev, V. V., & Kharchenko, A. V., 2022. In Silico ADME Profiling of Salubrinal and Its Analogues. *Future Pharmacol*, **2**(2), 160-197.

Zanger, U.M., Turpeinen, M., Klein, K., Schwab, M., 2008. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. *Anal Bioanal Chem*, **392**, 1093–1108.

Zendrato, R., Margono, S. A., 2005. Sintesis Diasetil Gamavuton-0 dengan Mmenggunakan Asetil Klorida sebagai Acylating Agent. *Majalah Farmasi Indonesia*, **17** (1), 25-31.

Zhang, D.-Y., Shao, L., Xu, J., Hu, X.-P., 2015. Copper-Catalyzed Asymmetric Formal [3 + 2] Cycloaddition of Propargylic Acetates with Hydrazines: Enantioselective Synthesis of Optically Active 2-Pyrazolines. *ACS Catal.*, **5**, 5026–5030.

Zhao, H., Tang, S., Xu, X., Du, L., 2016. Hydrogen Bonding Interaction between Atmospheric Gaseous Amides and Methanol. *Int J Mol Sci*, **18**, 4.

Zorrilla, E.P., 2017. Chapter 26 - Corticotropin-Releasing Factor Receptor Antagonists, in: Fink, G. (Ed.), Stress: Neuroendocrinology and Neurobiology. Academic Press, San Diego, pp. 265–277.

Zuehlke, A.D., Beebe, K., Neckers, L., Prince, T., 2015. Regulation and function of the human *HSP90AA1* gene. *Gene*, **570**, 8–16.